-
Government Regulated or Negotiated Drug Prices: Key Design Considerations Opens in a new window)
Most Americans—79 percent—consider U.S. prescription drug prices to be unreasonable, with almost 3 in 10 reporting they go without prescribed medications because of cost. -
COVID-19 Deaths And Hospitalizations Continue To Rise In The U.S. Opens in a new window)
Vaccines remain the best way to protect against serious illness. A week after the FDA gave full approval to Pfizer's COVID-19 vaccine, it's not known if that's nudging more people to get the shot.Comments
-
Voters Support Lowering the Medicare Eligibility Age and Prescription Drug Prices Opens in a new window)
As the coronavirus pandemic has shown us, there are many disparities in the United States in regards to healthcare coverage.Comments
-
WORLD PREVIEW 2021 Outlook to 2026
This year the World Preview focuses on how biopharma companies are navigating this new landscape, and the potential lasting effects of the pandemic.Comments
-
U.S. Data Show Rising 'Breakthrough' Infections Among Fully Vaccinated Opens in a new window)
The data, published in the U.S. Centers for Disease Control and Prevention's weekly report on death and disease, shows an increase in so-called "breakthrough" infections among fully vaccinated individuals.Comments
-
COVID Vaccine Protection Wanes Within Six Months - UK Researchers Opens in a new window)
The study was based on data from more than a million app users, comparing self-reported infections in vaccinated participants with cases in an unvaccinated control group.Comments
-
As Delta Spread, Covid-19 Vaccine eEfectiveness Against Infection Fell From 90% to 66% in One Key Study Opens in a new window)
The study, known as HEROES-RECOVER, includes more than 4,000 health care workers, first responders, and other frontline workers in eight locations across six states, all of whom have been tested weekly for infection with SARS-CoV-2.Comments
-
Takeda, CSL Hereditary Angioedema Meds Need Steep Discounts Following Real-World Evidence Review, ICER Says Opens in a new window)
With real-world data in hand, the Institute for Clinical and Economic Review (ICER) is retooling its cost-effectiveness models for three rare disease drugs. And the new discounts it has in mind are steep.Comments
-
Vaccines Prevented Fewer Infections as Delta Emerged, Federal Researchers Find. Opens in a new window)
Coronavirus vaccines provided strong protection against infection for essential workers earlier this year, but have become less effective.Comments
-
ICER Releases Draft Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy
The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report assessing the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy.Comments
-
MIRROR, MIRROR 2021
Reflecting Poorly: Health Care in the U.S. Compared to Other High-Income CountriesComments
-
NICE Changes to Provide Faster, Fairer Access to New Drugs and Devices
NICE is changing how it assess new drugs, devices, diagnostics and digital technologies to provide faster and fairer access in the NHS. The changes will also improve the way it works with patients, the NHS and the life sciences industry.Comments
-
How Federal Drug-Pricing Proposals Could Affect Medicaid Opens in a new window)
Medicare negotiation and inflation rebates would likely have the unintended effect of modestly lowering the rebates manufacturers must now pay state Medicaid programs, thereby raising federal and state Medicaid prescription drug costs.Comments
-
Will Reducing Drug Prices Slow Innovation?
The pharmaceutical industry has long argued that high drug prices reflect the high cost of innovation and that reducing drug prices would necessarily slow the pipeline of new drugs.@CIDSAexperts, @WestHealth, @bentleyu
Comments
-
Drug Price Reduction Could Have No Impact on Future Approvals, Study Finds Opens in a new window)
New research shows that drug price reductions under the US’s H.R. 3 policy could have no impact on innovation in the pharmaceutical industry.Comments
Comments